Background The risk of biochemical recurrence (BCR) following radical prostatectomy for pathologic Gleason 7 prostate cancer varies according to the proportion of Gleason 4 component. Objective We sought to explore the value of several novel quantitative metrics of Gleason 4 disease for the prediction of BCR in men with Gleason 7 disease. Design, setting, and participants We analyzed a cohort of 2630 radical prostatectomy cases from 1990–2007. All pathologic Gleason 7 cases were identified and assessed for quantity of Gleason pattern 4. Three methods were used to quantify the extent of Gleason 4: a quantitative Gleason score (qGS) based on the proportion of tumor composed of Gleason pattern 4, a size-weighted score (swGS) incorporating the overall quantity of Gleason 4, and a size index (siGS) incorporating the quantity of Gleason 4 based on the index lesion. Outcome measurements and statistical analysis Associations between the above metrics and BCR were evaluated using Cox proportional hazards regression analysis. Results and limitations qGS, swGS, and siGS were significantly associated with BCR on multivariate analysis when adjusted for traditional Gleason score, age, prostate specific antigen, surgical margin, and stage. Using Harrell's c-index to compare the scoring systems, qGS (0.83), swGS (0.84), and siGS (0.84) all performed better than the traditional Gleason score (0.82). Conclusions Quantitative measures of Gleason pattern 4 predict BCR better than the traditional Gleason score. Patient summary In men with Gleason 7 prostate cancer, quantitative analysis of the proportion of Gleason pattern 4 (quantitative Gleason score), as well as size-weighted measurement of Gleason 4 (size-weighted Gleason score), and a size-weighted measurement of Gleason 4 based on the largest tumor nodule significantly improve the predicted risk of biochemical recurrence compared with the traditional Gleason score.
Bibliographical noteFunding Information:
Funding/Support and role of the sponsor: This work was supported in part by Department of Defense PCRP grant numbers W81XWH-10-2-0046 and W81XWH-14-2-0185 and NCI/NIH grant number UO1 CA99-012.
© 2015 European Association of Urology
- Gleason score
- Neoplasm grading
- Neoplasm recurrence
- Prostatic neoplasms
- Risk assessment
- Tumor volume